Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Ferguson

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Current Opinion in Cardiology|December 17, 2008
Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?Marc Cohen, James J Ferguson
Circulation|November 26, 2003
Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?Elliott M Antman, James J Ferguson
The Journal of Invasive Cardiology|October 2, 2007
Of Swiss alchemists and road hazardsJames J Ferguson, Cindy W Tom
American Heart Journal|August 30, 2005
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trialKenneth W Mahaffey, James J Ferguson
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 29, 2008
Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicineJohn F Canales, James J Ferguson
Nature Clinical Practice. Cardiovascular Medicine|August 26, 2006
OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes?James J Ferguson, Gary M Idelchik
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 1, 2003
Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendationsGlenn N Levine, James J Ferguson
Critical Pathways in Cardiology|March 15, 2008
Use of enoxaparin in patients undergoing percutaneous coronary interventionRajan A Kadakia, James J Ferguson
The Journal of Invasive Cardiology|May 4, 2005
Direct stenting and placement of a distal protection device after laser angioplasty in a saphenous vein graft with severe stenosisShun Kohsaka, James J Ferguson, Eduardo Hernandez-Vila
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 27, 2017
Controversies surrounding authorship of manuscripts by industry employees: academic and industry perspectivesNathaniel R Smilowitz, James J Ferguson, Giora Weisz
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Current Opinion in Cardiology|December 17, 2008
Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?Marc Cohen, James J Ferguson
Circulation|November 26, 2003
Should evidence-based proof of efficacy as defined for a specific therapeutic agent be extrapolated to encompass a therapeutic class of agents?Elliott M Antman, James J Ferguson
The Journal of Invasive Cardiology|October 2, 2007
Of Swiss alchemists and road hazardsJames J Ferguson, Cindy W Tom
American Heart Journal|August 30, 2005
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trialKenneth W Mahaffey, James J Ferguson
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 29, 2008
Low-molecular-weight heparins : mechanisms, trials, and role in contemporary interventional medicineJohn F Canales, James J Ferguson
Nature Clinical Practice. Cardiovascular Medicine|August 26, 2006
OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes?James J Ferguson, Gary M Idelchik
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 1, 2003
Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendationsGlenn N Levine, James J Ferguson
Critical Pathways in Cardiology|March 15, 2008
Use of enoxaparin in patients undergoing percutaneous coronary interventionRajan A Kadakia, James J Ferguson
The Journal of Invasive Cardiology|May 4, 2005
Direct stenting and placement of a distal protection device after laser angioplasty in a saphenous vein graft with severe stenosisShun Kohsaka, James J Ferguson, Eduardo Hernandez-Vila
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|December 27, 2017
Controversies surrounding authorship of manuscripts by industry employees: academic and industry perspectivesNathaniel R Smilowitz, James J Ferguson, Giora Weisz
Pageof 7